Page - 116 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Alcantaraet al. Molecular imagingofbreast cancer Lobbes,M.B. I., Prevos,R., Smidt,M.,Tjan-Heijnen,V.C.G.,VanGoethem,M., Schipper,R., et al. (2013).Theroleofmagnetic resonance imaging inassessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 4, 163–175.doi:10.1007/s13244-013-0219-y Lodhia, J.,Mandarano,G., Ferris,N., Eu, P., andCowell, S. (2010).Development and use of iron oxide nanoparticles (Part 1): synthesis of iron oxide nanoparticles for MRI. Biomed. Imaging Interv. J. 6:e12. doi: 10.2349/biij. 6.2.e12 Mann,R.M.,Kuhl,C.K.,Kinkel,K., andBoetes,C.(2008).BreastMRI:guidelines fromtheEuropeanSociety ofBreast Imaging.Eur.Radiol.18, 1307–1318. doi: 10.1007/s00330-008-0863-7 McLelland, R., Hendrick, R. E., Zinninger,M.D., andWilcox, P. A. (1991). The American College of Radiology Mammography Accreditation Program. AJR Am.J.Roentgenol.157,473–479.doi:10.2214/ajr.157.3.1872231 Meier, R., Henning, T. D., Boddington, S., Tavri, S., Arora, S., Piontek, G., et al. (2010). Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology 255, 527–535. doi: 10.1148/radiol.10090050 Mercado,C.L. (2014).BI-RADSupdate.Radiol.Clin.NorthAm.52,481–487.doi: 10.1016/j.rcl.2014.02.008 Mirna Therapeutics, I. (2014). A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection, ed C.P.R.I.O. Available online at: ClinicalTrials.gov Morris,E.A.,Comstock,C.E.,Lee,C.H., etal. (2013). “ACRBI-RADS®magnetic resonanceimaging,”inACRBI-RADS®Atlas,BreastImagingReportingandData System (Reston,VA:AmericanCollegeofRadiology). Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A., and Thierry, A. R. (2014). Multi-marker analysis of circulating cell-free DNA toward per- sonalized medicine for colorectal cancer. Mol. Oncol. 8, 927–941. doi: 10.1016/j.molonc.2014.02.005 Mulrane,L.,Klinger,R.,McGee,S.F.,Gallagher,W.M.,andO’connor,D.P.(2014). microRNAs:anewclassofbreastcancerbiomarkers.ExpertRev.Mol.Diagn.14, 347–363.doi:10.1586/14737159.2014.901153 Ng,E.K.O.,Li,R.,Shin,V.Y., Jin,H.C.,Leung,C.P.H.,Ma,E.S.K., etal. (2013). CirculatingmicroRNAsasspecificbiomarkers forbreastcancerdetection.PLoS ONE8:e53141.doi:10.1371/journal.pone.0053141 Oliveira,S.,VanDongen,G.A.,Stigter-VanWalsum,M.,Roovers,R.C.,Stam,J.C., Mali,W., etal. (2012).Rapidvisualizationofhumantumorxenografts through optical imagingwith a near-infraredfluorescent anti-epidermal growth factor receptornanobody.Mol. Imaging11,33–46. Pace, L., Nicolai, E., Luongo, A., Aiello, M., Catalano, O. A., Soricelli, A., et al. (2014). Comparison of whole-body PET/CT and PET/MRI in breast can- cer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur. J. Radiol. 83, 289–296. doi: 10.1016/j.ejrad.2013.11.002 Partridge, S. C. (2008). Future applications and innovations of clinical breast magnetic resonance imaging. Top. Magn. Reson. Imaging 19, 171–176. doi: 10.1097/RMR.0b013e31818a4090 Partridge, S. C., and McDonald, E. S. (2013). Diffusion Weighted Magnetic Resonance Imaging of the Breast: Protocol Optimization, Interpretation, and Clinical Applications.Magn. Reson. Imaging Clin. N. Am. 21, 601–624. doi: 10.1016/j.mric.2013.04.007 Penuelas, I., Dominguez-Prado, I., Garcia-Velloso, M. J., Marti-Climent, J. M., Rodriguez-Fraile, M., Caicedo, C., et al. (2012). PET tracers for clini- cal imaging of breast cancer. J. Oncol. 2012, 710561. doi: 10.1155/2012/ 710561 Peters, N.H., Borel Rinkes, I.H., Zuithoff, N. P.,Mali,W. P.,Moons, K.G., and Peeters, P.H. (2008).Meta-analysis ofMR imaging in the diagnosis of breast lesions.Radiology246,116–124.doi:10.1148/radiol.2461061298 Poellinger,A. (2012).Near-infrared imagingofbreastcancerusingopticalcontrast agents. J.Biophotonics5,815–826.doi:10.1002/jbio.201200123 Polyak, K. (2014). Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat. Med. 20, 344–346. doi: 10.1038/ nm.3518 Rhee, C.M., Bhan, I., Alexander, E. K., and Brunelli, S. M. (2012). Association between iodinatedcontrastmedia exposure and incidenthyperthyroidismand hypothyroidism. Arch. Intern. Med. 172, 153–159. doi: 10.1001/archintern- med.2011.677 Robbins, J. B. P., Pozniak, M. A., (2010). Contrast Media Tutorial. Reston, VA: American College of Radiology. Available online at: https://www.radiology. wisc.edu/fileShelf/contrastCorner/files/ContrastAgentsTutorial.pdf Rosen, J. E.,Chan,L., Shieh,D.-B., andGu,F.X. (2012). Ironoxidenanoparticles for targetedcancer imaginganddiagnostics.Nanomed.Nanotechnol.Biol.Med. 8,275–290.doi:10.1016/j.nano.2011.08.017 Sano,K.,Mitsunaga,M.,Nakajima,T.,Choyke,P.L., andKobayashi,H. (2012). In vivo breast cancer characterization imaging using twomonoclonal antibodies activatably labeledwithnear infraredfluorophores.BreastCancerRes.14,R61. doi:10.1186/bcr3167 Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., et al. (2010). Magnetic resonance imaging of the breast: recommenda- tions from the EUSOMAworking group. Eur. J. Cancer 46, 1296–1316. doi: 10.1016/j.ejca.2010.02.015 Scaperrotta,G.,Ferranti,C.,Costa,C.,Mariani,L.,Marchesini,M.,Suman,L.,etal. (2008).Roleofsonoelastographyinnon-palpablebreast lesions.Eur.Radiol.18, 2381–2389.doi:10.1007/s00330-008-1032-8 Segal, E., Sirlin, C. B., Ooi, C., Adler, A. S., Gollub, J., Chen, X., et al. (2007). Decoding global gene expression programs in liver cancer by noninvasive imaging.Nat.Biotechnol.25,675–680.doi:10.1038/nbt1306 Seoane, J., and De Mattos-Arruda, L. (2014). The challenge of intratu- mour heterogeneity in precision medicine. J. Intern. Med. 276, 41–51. doi: 10.1111/joim.12240 Si, H., Sun, X., Chen, Y., Cao, Y., Chen, S.,Wang, H., et al. (2013). Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 139, 223–229. doi: 10.1007/s00432-012-1315-y Sun, Y., Kim H. S., Park, J., Li, M., Tian, L., Choi, Y., et al. (2014). MRI of breast tumor initiating cells using the extra domain-Bof fibronectin targeting nanoparticlesTheranostics4,845–857.doi:10.7150/thno.8343 Swaby, R., Sharma, C. N., and Jordan, V. C. (2007). SERMs for the treatment and prevention of breast cancer.Rev. Endocr.Metab. Disord. 8, 229–239. doi: 10.1007/s11154-007-9034-4 Thakor, A. S., and Gambhir, S. S. (2013). Nanooncology: the future of cancer diagnosisandtherapy.CACancer J.Clin.63,395–418.doi:10.3322/caac.21199 Tozaki, M., Sakamoto, M., Oyama, Y., Maruyama, K., and Fukuma, E. (2010). Predicting pathological response to neoadjuvant chemotherapy in breast can- cerwithquantitative1HMRspectroscopyusing theexternal standardmethod. J.Magn.Reson. Imaging31,895–902.doi:10.1002/jmri.22118 Tsougos, I., Svolos, P., Kousi, E., Athanassiou, E., Theodorou, K., Arvanitis, D., et al. (2014). The contribution of diffusion tensor imaging andmagnetic res- onance spectroscopy for thedifferentiationofbreast lesions at 3T.ActaRadiol. 55,14–23.doi:10.1177/0284185113492152 Utting,M.,Werner,W.,Dahse,R.,Schubert,J.,andJunker,K.(2002).Microsatellite analysis of free tumorDNA in urine, serum, and plasma of patients: amin- imally invasive method for the detection of bladder cancer. Clin. Cancer Res.8,35–40.Availableonlineat:http://clincancerres.aacrjournals.org/content/ 8/1/35.full VanDerPloeg, I.M.,Olmos,R.A.,Kroon,B.B.,Rutgers, E. J., andNieweg,O.E. (2009).ThehiddensentinelnodeandSPECT/CTinbreastcancerpatients.Eur. J.Nucl.Med.Mol. Imaging 36,6–11.doi:10.1007/s00259-008-0910-2 VanDe Ven, S.M., Elias, S. G., Chan, C. T., Miao, Z., Cheng, Z., De, A., et al. (2012). Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. Clin. CancerRes.18,1073–1081.doi:10.1158/1078-0432.CCR-10-3213 Verbeek, F. P., Troyan, S. L.,Mieog, J. S., Liefers, G. J.,Moffitt, L. A., Rosenberg, M., et al. (2014).Near-infrared fluorescence sentinel lymphnodemapping in breast cancer: amulticenter experience.BreastCancerRes.Treat.143,333–342. doi:10.1007/s10549-013-2802-9 Von Karsa, L., and Arrossi, S. (2013). Development and implementa- tion of guidelines for quality assurance in breast cancer screening: the European experience. Salud Publica Mex. 55, 318–328. Available online at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342013000 400010&lng=en Waldherr, C., Cerny, P., Altermatt,H. J., Berclaz, G., Ciriolo,M., Buser, K., et al. (2013). Value of one-view breast tomosynthesis versus two-viewmammogra- phy in diagnostic workup of women with clinical signs and symptoms and inwomen recalled from screening.AJRAm. J. Roentgenol. 200, 226–231. doi: 10.2214/AJR.11.8202 Frontiers inChemistry | ChemicalEngineering December2014 |Volume2 |Article112 | 116